BCAR1/p130Cas expression in untreated and acquired tamoxifen-resistant human breast carcinomas.

Abstract	High BCAR1/p130Cas expression in primary breast tumour cytosol predicts a poor chance of response recurrent disease to tamoxifen treatment in patients with oestrogen receptor (ER)-positive breast carcinomas. In this study, we assessed whether BCAR1/p130Cas expression is altered during acquisition of anti-oestrogen resistance. BCAR1/p130Cas protein was quantitatively measured by chemiluminescent Western blot analysis in the cytosol of 34 predominantly ER(+) carcinomas that initially responded to primary tamoxifen treatment and subsequently progressed (n = 22 ) or developed during adjuvant tamoxifen treatment (n = 12) and compared to 54 untreated ER(+) human breast carcinomas. We did not detect significant differences in the level of BCAR1/p130Cas protein in untreated and acquired tamoxifen-resistant carcinomas. Our results indicate that in tumour progression towards tamoxifen resistance, increase of BCAR1/p130Cas may be only one of the molecular mechanisms. Thus, high BCAR1/p130Cas protein levels appear to be a hallmark for intrinsic resistance to tamoxifen in breast carcinomas.
Authors	S van der Flier, C M Chan, A Brinkman, M Smid, S R Johnston, L C Dorssers, M Dowsett
Journal	International journal of cancer (Int J Cancer) Vol. 89 Issue 5 Pg. 465-8 (Sep 20 2000) ISSN: 0020-7136 [Print] United States
PMID	11008210 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright	Copyright 2000 Wiley-Liss, Inc.
Chemical References	BCAR1 protein, human Crk-Associated Substrate Protein Estrogen Antagonists Phosphoproteins Proteins Receptors, Estrogen Retinoblastoma-Like Protein p130 Tamoxifen
Topics	Adult Aged Aged, 80 and over Breast Neoplasms (drug therapy, genetics) Crk-Associated Substrate Protein Drug Resistance, Neoplasm Estrogen Antagonists (therapeutic use) Female Humans Middle Aged Phosphoproteins (analysis, genetics) Proteins Receptors, Estrogen (analysis) Retinoblastoma-Like Protein p130 Tamoxifen (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!